Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.

In English

Författare

  • Nina Mononen
  • Eija H Seppälä
  • Priya Duggal
  • Ville Autio
  • Tarja Ikonen
  • Pekka Ellonen
  • Juha Saharinen
  • Janna Saarela
  • Mauno Vihinen
  • Teuvo L J Tammela
  • Olli Kallioniemi
  • Joan E Bailey-Wilson
  • Johanna Schleutker
Visa allt

Summary, in English

Several candidate genes along androgen pathway have been suggested to affect prostate cancer risk but no single gene seems to be overwhelmingly important for a large fraction of the patients. In this study, we first screened for variants in candidate genes and then chose to explore the association between 18 variants and prostate cancer risk by genotyping DNA samples from unselected (n = 847) and familial (n = 121) prostate cancer patients and population controls (n = 923). We identified a novel single nucleotide polymorphism (SNP) in the CYP19A1 gene, T201M, with a mild significant association with prostate cancer [odds ratio (OR), 2.04; 95% confidence interval (95% CI), 1.03-4.03; P = 0.04]. Stratified analysis revealed that this risk was most apparent in patients with organ-confined (T(1)-T(2)) and low-grade (WHO grade 1) tumors (OR, 5.42; 95% CI, 2.33-12.6; P < 0.0001). In contrast, CYP17A1 -34T>C alteration was associated with moderate to poorly differentiated (WHO grade 2-3) organ-confined disease (OR, 1.42; 95% CI, 1.09-1.83; P = 0.007). We also tested a multigenic model of prostate cancer risk by calculating the joint effect of CYP19A1 T201M with five other common SNPs. Individuals carrying both the CYP19A1 and KLK3 -252A>G variant alleles had a significantly increased risk for prostate cancer (OR, 2.87; 95% CI, 1.10-7.49; P = 0.03). In conclusion, our results suggest that several SNPs along the androgen pathway, especially in CYP19A1 and CYP17A1, may influence prostate cancer development and progression. These genes may have different contributions to distinct clinical subsets as well as combinatorial effects in others illustrating that profiling and joint analysis of several genes along each pathway may be needed to understand genetic contributions to prostate cancer etiology.

Publiceringsår

2006

Språk

Engelska

Sidor

743-747

Publikation/Tidskrift/Serie

Cancer Research

Volym

66

Issue

2

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for Cancer Research Inc.

Ämne

  • Medical Genetics

Nyckelord

  • Androgens: biosynthesis
  • Aromatase: genetics
  • Prostatic Neoplasms: genetics
  • Prostatic Neoplasms: physiopathology
  • Steroid 17-alpha-Hydroxylase: genetics

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1538-7445